Atezolizumab (Tecentrip) and durvalumab are humanized engineered IgG1 monoclonal antibodies against PD-L1, which can inhibit PD-L1 binding to PD-1 or B7-1, thereby further enhancing the immune response to cancer cells [185]. Here, CD274 is linked to cancer.